The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk patients, the test results can guide patient suitability for active surveillance. For intermediate-risk patients, there’s a predictive test result to determine if ST-ADT is beneficial. And for high-risk patients, there’s insights to guide abiraterone usage along with radiation therapy and LT-ADT. Listen to Drs. Calvin Chao (Artera), Kenneth Nepple (University of Iowa), and Steve Seyedin (UCSF) on how the test has impacted their clinical practice, as well as the nuances of how to interpret the test results along with other patient factors to optimize cancer care.
Fill out the form below to view the recording…
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk patients, the test results can guide patient suitability for active surveillance. For intermediate-risk patients, there’s a predictive test result to determine if ST-ADT is beneficial. And for high-risk patients, there’s insights to guide abiraterone usage along with radiation therapy and LT-ADT.
Listen to Drs. Calvin Chao (Artera), Kenneth Nepple (University of Iowa), and Steve Seyedin (UCSF) on how the test has impacted their clinical practice, as well as the nuances of how to interpret the test results along with other patient factors to optimize cancer care.
